Latest Breaking News On - Arshadm khanani - Page 4 : comparemela.com

Opthea Appoints Arshad M Khanani, MD, MA, FASRS, as Chief Medical Advisor - Opthea (NASDAQ:OPT)

MELBOURNE, Australia, Feb. 19, 2024 (GLOBE NEWSWIRE) Opthea Limited ((ASX:OPT, NASDAQ:OPT, "Opthea")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive

United statesUniversity of nevadaArshadm khananiFrederic guerardRudi michelsonClinical researchOpthea limitedRetina societyExchange commissionMonsoon communicationsMacula societyAstellas companyReno school of medicineSierra eye associatesWilmer eye institute at johns hopkins universityAmerican society of retina specialists

Adverum Biotechnologies (ADVM) Reports Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial

Adverum Biotechnologies (ADVM) Reports Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomArshadm khananiLaurent fischerArshad khananiClinical research at sierra eye associatesClinical associate professor at university of nevadaExchange commissionMeeting of the macula societyHealthcare products regulatory agencyAdverum biotechnologies incAdverum biotechnologiesAnnual meetingIntravitreal gene therapyNeovascular age related macular degenerationPreliminary resultsManaging partner

Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD

Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United kingdomArshad khananiArshadm khananiLaurent fischerClinical research at sierra eye associatesHealthcare products regulatory agencyClinical associate professor at university of nevadaAdverum biotechnologies incMeeting of the macula societyExchange commissionSafety dataAnnual meetingIntravitreal gene therapyNeovascular age related macular degenerationPreliminary resultsManaging partner

4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD

51 wet AMD patients with severe disease activity and high treatment burden were randomized to high or low dose 4D-150 or aflibercept control regimen4D-150 was well tolerated with a favorable.

United statesArshadm khananiDavid kirnRobert kimJulian peiKatherine smithCorporate communicationsProgram updatesExchange commissionGlobenewswire incClinical data programEuropean unionClinic researchSierra eye associatesD molecular therapeutics incMolecular therapeutics

4DMT Presents Positive Interim Data from Randomized Phase 2

51 wet AMD patients with severe disease activity (mean of 442 µm central subfield thickness & presence of retinal fluid) and high treatment burden.

United statesDavid kirnKatherine smithRobert kimJulian peiArshadm khananiClinic research at sierra eye associatesProgram updatesEuropean unionCorporate communicationsClinical data programExchange commissionMolecular therapeuticsChief executive officerChief medicalClinic research